Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
The company also reported completion of enrollment in the third dosing cohort of its ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.Bio-Path Holdings, Inc., (NASDAQ:BPTH) stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro.
Bio-Path控股公司（納斯達克：BPTH）股票週二交易較高，成交量爲2589萬，而平均成交量爲32.897萬，數據來自Benzinga Pro。
The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application.
公司啓動了一個治療方案，開發BP1001-A來治療肥胖症和相關代謝性疾病。這個方案標誌着第一次應用DNAbilize技術來開發非癌症應用。
The company expects to begin preclinical studies to confirm these assumptions in the fourth quarter of 2024. These studies are expected to provide crucial insights into the mechanism and efficacy of BP1001-A in enhancing insulin sensitivity and reveal its therapeutic potential for obesity and Type 2 diabetes.
公司預計將在2024年第四季度開始臨床前研究，以證實這些假設。這些研究預計將爲BP1001-A在增強胰島素敏感性方面的機制和功效提供重要見解，並揭示其在肥胖症和2型糖尿病治療中的治療潛力。
The company also reported completion of enrollment in the third dosing cohort of its ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
該公司還報告完成了第10/10億期臨床試驗中第三個劑量組的招募，該試驗評估BP1002用於難治/復發急性髓樣白血病（AML）患者，包括venetoclax耐藥患者。
AbbVie Inc (NYSE:ABBV) and Roche Holdings AG's (OTC:RHHBY) Genentech have partnered for Venclexta (venetoclax).
AbbVie公司（紐交所：ABBV）和羅氏控股AG（場外交易：RHHBY）的基因泰克公司（Genentech）已合作開發Venclexta（venetoclax）。
In August, Bio-Path provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.
今年8月，Bio-Path提供了BP1001-A在固體腫瘤患者中進行的第10/10億期臨床試驗的最新進展，並報告了正在進行的前司各貝生在急性髓樣白血病中的第2期三聯療法研究的持續患者進展。
The cohort enrolled more quickly than projected, within six weeks, which underscores the ongoing need for new treatment options for these relapsed/refractory patients.
該隊列比預期更快完成了招募，只用了六週，這凸顯了對這些復發/難治患者需要新治療選擇的持續需求。
Bio-Path says that by targeting the key protein involved in the venetoclax treatment at the mRNA level, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
Bio-Path表示，通過在mRNA水平上瞄準涉及venetoclax治療的關鍵蛋白，BP1002可能克服和預防一些影響venetoclax治療的耐藥機制。
Price Action: At last check Tuesday, BPTH stock was up 51.50% at $1.30 during the premarket session.
價格走勢：截至週二最後一次查詢，BPTH股票在盤前交易時上漲了51.50%，報1.30美元。
- Next-Gen Nvidia GPUs Could Be Revealed at CES 2025 – What You Need to Know.
- 英偉達的下一代GPU可能會在2025年的CES上揭曉 - 你需要知道的事情。
譯文內容由第三人軟體翻譯。